<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771340</url>
  </required_header>
  <id_info>
    <org_study_id>IT-003</org_study_id>
    <nct_id>NCT02771340</nct_id>
  </id_info>
  <brief_title>Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma</brief_title>
  <official_title>A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iconic Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iconic Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, biological activity,&#xD;
      pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal&#xD;
      doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo&#xD;
      enucleation or brachytherapy of the affected eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>30 days (plus or minus 5 days) after surgical procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Levels of ICON-1.</measure>
    <time_frame>Baseline to 1 day after last dose of ICON-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA) From Baseline to End of Study</measure>
    <time_frame>Baseline to on or 1 day prior to surgical procedure day</time_frame>
    <description>Best-corrected visual acuity (BCVA) will be measured for each eye, pre treatment prior to dilating eyes, using standard Early Treatment Diabetic Retinopathy Study (ETDRS)-like retro-illuminated charts. BCVA will be recorded as the total letter score in each eye.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Choroid Neoplasm</condition>
  <arm_group>
    <arm_group_label>ICON-1 0.3 mg Singe Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICON-1 0.3 mg Repeat Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICON-1 0.6 mg Repeat Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ICON-1</intervention_name>
    <description>Intravitreal injection of ICON-1</description>
    <arm_group_label>ICON-1 0.3 mg Repeat Dosing</arm_group_label>
    <arm_group_label>ICON-1 0.3 mg Singe Dose</arm_group_label>
    <arm_group_label>ICON-1 0.6 mg Repeat Dosing</arm_group_label>
    <other_name>human Immuno-conjugate 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females of any race at least 18 years of age&#xD;
&#xD;
          -  Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in&#xD;
             the study eye&#xD;
&#xD;
          -  Planned enucleation or brachytherapy of the study eye due to uveal melanoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uveal melanoma in the study eye originating in the anterior uveal tract (iris)&#xD;
&#xD;
          -  Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)&#xD;
&#xD;
          -  Woman who is pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Burian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Iconic Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cureom.org</url>
    <description>CURE OM (Community United for Research and Education of Ocular Melanoma)</description>
  </link>
  <link>
    <url>http://www.ocularmelanoma.org</url>
    <description>Ocular Melanoma Foundation (OMF)</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Choroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02771340/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ICON-1 0.3 mg Singe Dose</title>
          <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="P2">
          <title>ICON-1 0.3 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="P3">
          <title>ICON-1 0.6 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ICON-1 0.3 mg Singe Dose</title>
          <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="B2">
          <title>ICON-1 0.3 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="B3">
          <title>ICON-1 0.6 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.5" spread="0.7"/>
                    <measurement group_id="B2" value="64.3" spread="4.0"/>
                    <measurement group_id="B3" value="56.2" spread="17.2"/>
                    <measurement group_id="B4" value="63.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Adverse Events</title>
        <time_frame>30 days (plus or minus 5 days) after surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICON-1 0.3 mg Singe Dose</title>
            <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O2">
            <title>ICON-1 0.3 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O3">
            <title>ICON-1 0.6 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phototoxic Injury/Surgical Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctival Haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctival hyperaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Punctate Keratitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iridocyclitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular Pressure Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Plasma Levels of ICON-1.</title>
        <time_frame>Baseline to 1 day after last dose of ICON-1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICON-1 0.3 mg Singe Dose</title>
            <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O2">
            <title>ICON-1 0.3 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O3">
            <title>ICON-1 0.6 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plasma Levels of ICON-1.</title>
          <units>ng/ml-All LLOQ</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Best Corrected Visual Acuity (BCVA) From Baseline to End of Study</title>
        <description>Best-corrected visual acuity (BCVA) will be measured for each eye, pre treatment prior to dilating eyes, using standard Early Treatment Diabetic Retinopathy Study (ETDRS)-like retro-illuminated charts. BCVA will be recorded as the total letter score in each eye.</description>
        <time_frame>Baseline to on or 1 day prior to surgical procedure day</time_frame>
        <population>End-of-Study assessments obtained for brachytherapy (placing radioactive material in the eye) patients only.</population>
        <group_list>
          <group group_id="O1">
            <title>ICON-1 0.3 mg Singe Dose</title>
            <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O2">
            <title>ICON-1 0.3 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
          <group group_id="O3">
            <title>ICON-1 0.6 mg Repeat Dosing</title>
            <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Best Corrected Visual Acuity (BCVA) From Baseline to End of Study</title>
          <description>Best-corrected visual acuity (BCVA) will be measured for each eye, pre treatment prior to dilating eyes, using standard Early Treatment Diabetic Retinopathy Study (ETDRS)-like retro-illuminated charts. BCVA will be recorded as the total letter score in each eye.</description>
          <population>End-of-Study assessments obtained for brachytherapy (placing radioactive material in the eye) patients only.</population>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="4.2"/>
                    <measurement group_id="O2" value="-4.3" spread="11.8"/>
                    <measurement group_id="O3" value="-3.6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the course of the study and for 30 days last post injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ICON-1 0.3 mg Singe Dose</title>
          <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="E2">
          <title>ICON-1 0.3 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
        <group group_id="E3">
          <title>ICON-1 0.6 mg Repeat Dosing</title>
          <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart&#xD;
ICON-1: Intravitreal injection of ICON-1</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Phototoxic Injury/Surgical Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabriela Burian, M.D.</name_or_title>
      <organization>Iconic Therapeutics</organization>
      <phone>6504371000</phone>
      <email>gburian@iconictherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

